Related references
Note: Only part of the references are listed.Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial
Shengli Xia et al.
LANCET INFECTIOUS DISEASES (2021)
The Proportion of SARS-CoV-2 Infections That Are Asymptomatic A Systematic Review
Daniel P. Oran et al.
ANNALS OF INTERNAL MEDICINE (2021)
Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition
Allison J. Greaney et al.
CELL HOST & MICROBE (2021)
A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity
Vincent Legros et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2021)
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
Merryn Voysey et al.
LANCET (2021)
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial
Raches Ella et al.
LANCET INFECTIOUS DISEASES (2021)
Correlates of protection against SARS-CoV-2 in rhesus macaques
Katherine McMahan et al.
NATURE (2021)
Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection
Jennifer M. Dan et al.
SCIENCE (2021)
SARS-CoV-2 Infection Severity Is Linked to Superior Humoral Immunity against the Spike
Jenna J. Guthmiller et al.
MBIO (2021)
Community prevalence of SARS-CoV-2 in England from April to November, 2020: results from the ONS Coronavirus Infection Survey
Koen B. Pouwels et al.
LANCET PUBLIC HEALTH (2021)
The antigenic anatomy of SARS-CoV-2 receptor binding domain
Wanwisa Dejnirattisai et al.
CELL (2021)
SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines
Xiaoying Shen et al.
CELL HOST & MICROBE (2021)
Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization
Zhuoming Liu et al.
CELL HOST & MICROBE (2021)
Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2
Saman Saadat et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment
Olivier J. Wouters et al.
LANCET (2021)
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
Merryn Voysey et al.
LANCET (2021)
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
Denis Y. Logunov et al.
LANCET (2021)
SARS-CoV-2 variants and ending the COVID-19 pandemic
Arnaud Fontanet et al.
LANCET (2021)
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
Zhiwei Wu et al.
LANCET INFECTIOUS DISEASES (2021)
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
Yanjun Zhang et al.
LANCET INFECTIOUS DISEASES (2021)
Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies
Dami A. Collier et al.
NATURE (2021)
SARS-CoV-2 evolution during treatment of chronic infection
Steven A. Kemp et al.
NATURE (2021)
BNT162b vaccines protect rhesus macaques from SARS-CoV-2
Annette B. Vogel et al.
NATURE (2021)
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma
Constantinos Kurt Wibmer et al.
NATURE MEDICINE (2021)
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
Noa Dagan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine
Florian Krammer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine
Kai Wu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Neutralizing Activity of BNT162b2-Elicited Serum
Yang Liu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera
Alexander Muik et al.
SCIENCE (2021)
Development and deployment of COVID-19 vaccines for those most vulnerable
Wayne C. Koff et al.
SCIENCE TRANSLATIONAL MEDICINE (2021)
Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19
Adam K. Wheatley et al.
NATURE COMMUNICATIONS (2021)
Covid-19 deaths in Africa: prospective systematic postmortem surveillance study
Lawrence Mwananyanda et al.
BMJ-BRITISH MEDICAL JOURNAL (2021)
The effect of spike mutations on SARS-CoV-2 neutralization
Chloe Rees-Spear et al.
CELL REPORTS (2021)
Serological evidence of human infection with SARS-CoV-2: a systematic review and meta-analysis
Xinhua Chen et al.
LANCET GLOBAL HEALTH (2021)
SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies
Markus Hoffmann et al.
CELL (2021)
SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera
Alona Kuzmina et al.
CELL HOST & MICROBE (2021)
Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant
Venkata Viswanadh Edara et al.
CELL HOST & MICROBE (2021)
Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study
Eleftheria Vasileiou et al.
LANCET (2021)
Report of the Independent Panel for Pandemic Preparedness and Response: making COVID-19 the last pandemic
Ellen Johnson Sirleaf et al.
LANCET (2021)
Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies
Delphine Planas et al.
NATURE MEDICINE (2021)
Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine
Matan Levine-Tiefenbrun et al.
NATURE MEDICINE (2021)
SARS-CoV-2 escaped natural immunity, raising questions about vaccines and therapies
Emanuele Andreano et al.
NATURE MEDICINE (2021)
Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
David S. Khoury et al.
NATURE MEDICINE (2021)
Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants
Laith J. Abu-Raddad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Interplay between Emerging SARS-CoV-2 Variants and Pandemic Control
Kathleen M. Neuzil
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
S. A. Madhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Vaccine Breakthrough Infections with SARS-CoV-2 Variants
Ezgi Hacisuleyman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant
V. Shinde et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice
Phillip Pymm et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)
A human coronavirus evolves antigenically to escape antibody immunity
Rachel T. Eguia et al.
PLOS PATHOGENS (2021)
SARS-CoV-2 seropositivity and subsequent infection risk in healthy young adults: a prospective cohort study
Andrew Letizia et al.
LANCET RESPIRATORY MEDICINE (2021)
Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight US Locations, December 2020-March 2021
Mark G. Thompson et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)
Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults A Randomized Clinical Trial
Nawal Al Kaabi et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans
Jackson S. Turner et al.
NATURE (2021)
SARS-CoV-2 Variants and Vaccines
Philip R. Krause et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
SARS-CoV-2 spike E484K mutation reduces antibody neutralisation
Sonia Jangra et al.
LANCET MICROBE (2021)
BNT162b2 vaccination effectively prevents the rapid rise of SARS-CoV-2 variant B.1.1.7 in high-risk populations in Israel
Ariel Munitz et al.
CELL REPORTS MEDICINE (2021)
Dynamics of Neutralizing Antibody Titers in the Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection
Katharine H. D. Crawford et al.
JOURNAL OF INFECTIOUS DISEASES (2021)
Infection fatality rate of COVID-19 inferred from seroprevalence data
John P. A. Ioannidis
BULLETIN OF THE WORLD HEALTH ORGANIZATION (2021)
A new coronavirus associated with human respiratory disease in China
Fan Wu et al.
NATURE (2020)
SARS-CoV-2: A New Song Recalls an Old Melody
Kanta Subbarao
CELL HOST & MICROBE (2020)
Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open -label, phase 1 trial
Till Koch et al.
LANCET INFECTIOUS DISEASES (2020)
Developing Covid-19 Vaccines at Pandemic Speed
Nicole Lurie et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2
Hui Wang et al.
CELL (2020)
Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus
Bette Korber et al.
CELL (2020)
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
Pedro M. Folegatti et al.
LANCET (2020)
Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology
Luca Piccoli et al.
CELL (2020)
Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques
Noe B. Mercado et al.
NATURE (2020)
SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness
Kizzmekia S. Corbett et al.
NATURE (2020)
ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques
Neeltje van Doremalen et al.
NATURE (2020)
SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls
Nina Le Bert et al.
NATURE (2020)
Global perspective of COVID-19 epidemiology for a full-cycle pandemic
John P. A. Ioannidis
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2020)
Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate
Amin Addetia et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2020)
SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies
Christopher O. Barnes et al.
NATURE (2020)
COVID-19 vaccines: time to talk about the uncertainties
Kanta Subbarao
NATURE (2020)
A dynamic COVID-19 immune signature includes associations with poor prognosis
Adam G. Laing et al.
NATURE MEDICINE (2020)
Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine
Cheryl Keech et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Decline of Humoral Responses against SARS-CoV-2 Spike in Convalescent Individuals
Guillaume Beaudoin-Bussieres et al.
MBIO (2020)
Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans
Jeffrey Seow et al.
NATURE MICROBIOLOGY (2020)
Compromised Humoral Functional Evolution Tracks with SARS-CoV-2 Mortality
Tomer Zohar et al.
CELL (2020)
Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications
Andrew T. Levin et al.
EUROPEAN JOURNAL OF EPIDEMIOLOGY (2020)
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
Maheshi N. Ramasamy et al.
LANCET (2020)
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host
Bina Choi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants
Yiska Weisblum et al.
ELIFE (2020)
Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients
Nisreen M. A. Okba et al.
EMERGING INFECTIOUS DISEASES (2020)
Mucosal Immunity: The Forgotten Arm of the Immune System Synopsis of the Pediatric Infectious Disease Society's 2017 Stanley A. Plotkin Lecture in Vaccinology
Peter F. Wright et al.
JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY (2019)
Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial
Kayvon Modjarrad et al.
LANCET INFECTIOUS DISEASES (2019)
Prospects for a MERS-CoV spike vaccine
Yusen Zhou et al.
EXPERT REVIEW OF VACCINES (2018)
Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen
Jesper Pallesen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV
William J. Liu et al.
ANTIVIRAL RESEARCH (2017)
T cell-mediated immune response to respiratory coronaviruses
Rudragouda Channappanavar et al.
IMMUNOLOGIC RESEARCH (2014)
Coronaviruses An RNA proofreading machine regulates replication fidelity and diversity
Mark R. Denison et al.
RNA BIOLOGY (2011)
A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial
Julie E. Martin et al.
VACCINE (2008)
Duration of humoral immunity to common viral and vaccine antigens
Ian J. Amanna et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice
K Subbarao et al.
JOURNAL OF VIROLOGY (2004)
Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity
UJ Buchholz et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Receptor-mediated immunoglobulin G transport across mucosal barriers in adult life: Functional expression of FcRn in the mammalian lung
GM Spiekermann et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2002)